Welcome to our dedicated page for Concord Medical SEC filings (Ticker: CCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Concord Medical Services Holdings Limited (NYSE: CCM) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. Concord Medical files an annual report on Form 20-F, which includes audited financial statements and detailed information about its oncology-focused operations, including its hospital business, network business and related financial metrics.
Concord Medical also furnishes Form 6-K current reports that cover a range of material information. Recent 6-K filings reference interim financial results for the first half of the year, announcements about annual general meetings of shareholders, changes in directors, and developments at its subsidiary Concord Healthcare Group Co., Ltd., which is listed on the Main Board of The Stock Exchange of Hong Kong Limited. Other 6-Ks transmit press releases on topics such as proton therapy milestones, licensing approvals for proton equipment and share placing activities at the subsidiary level.
Through these filings, readers can track how Concord Medical reports on its oncology hospital and network businesses, non-GAAP measures such as adjusted EBITDA as defined in its releases, and corporate governance and capital markets events. While foreign issuers like Concord Medical typically do not file Forms 10-K or 10-Q, their Form 20-F and Form 6-K submissions serve similar roles in disclosing annual and interim information.
On Stock Titan, AI-powered tools summarize lengthy filings, highlight key sections and help explain complex financial and regulatory language. Users can quickly identify important disclosures in Concord Medical’s Form 20-F and 6-Ks, and monitor ongoing updates related to its oncology services, proton therapy initiatives and subsidiary activities without reading every page in full.
Concord Medical Services Holdings Limited reported that Mr. Yue Yu resigned from its board of directors, effective September 29, 2025. The company states that his resignation is due to personal reasons and that it is not related to any disagreement with the company regarding its operations, policies, or practices. This indicates a board change without an underlying disclosed dispute over how the business is run.
Concord Medical Services Holdings Limited filed a report noting that its subsidiary, Concord Healthcare Group Co., Ltd., announced interim results on the Main Board of The Stock Exchange of Hong Kong Limited for the six months ended June 30, 2025. Concord Healthcare’s H shares trade on the HKSE under stock code 2453.HK, while the parent company remains listed on the NYSE under the symbol CCM.
The filing directs investors to the Hong Kong exchange website for detailed information on Concord Healthcare’s transactions and interim financial results.
Concord Medical Services Holdings Ltd. (NYSE: CCM) has filed a Form 6-K to disclose that its Hong Kong–listed subsidiary, Concord Healthcare Group Co., Ltd. (HKSE: 2453.HK), signed a placing agreement on 22 July 2025 with Guotai Junan Securities (Hong Kong). Under the agreement the placing agent will, on a best-effort basis, place 48,723,600 new H-shares with at least six independent investors at HK$5.54 per share. The issuance will be made under Concord Healthcare’s existing general mandate. No financial statements, earnings figures or projected proceeds were provided in the filing.
The transaction increases Concord Healthcare’s share count and is intended to raise fresh capital for the subsidiary; however, the filing does not state the specific use of proceeds or anticipated dilution for Concord Medical’s shareholders. The parent reiterates that additional details on the subsidiary’s Hong Kong transactions can be found on the HKEX website.
Concord Medical Services Holdings Limited (NYSE: CCM) filed a Form 6-K to disclose that its Hong Kong–listed subsidiary, Concord Healthcare Group Co., Ltd. (HKSE: 2453.HK), experienced a reduction in the stake held by one of its controlling shareholders. On 20 June 2025, Beijing Concord Medical Technology Co., Ltd. sold 32,800,000 H shares of Concord Healthcare via block trade at HK$6.12 per share, equal to approximately 4.46 % of Concord Healthcare’s issued share capital. The filing reiterates that Concord Healthcare’s H shares were listed on the HKSE on 9 January 2024 and directs investors to the HKSE website for transaction details.
No additional financial results, earnings data or strategic initiatives were reported in this 6-K.